Skip to content
Hair Pipeline
← Back to the pipeline

CG 428

CG 428 is in Phase 2 for chemotherapy-induced alopecia, developed by Legacy Healthcare.

A Legacy Healthcare botanical lotion trialled during chemotherapy and, in a published pilot, in persistent post-chemotherapy hair loss, with nothing registered since 2019.

This programme is no longer being actively pursued.

Monthly digest of verified phase changes. A confirmation link goes out first; unsubscribe is one click on every mail.

Developed by
Legacy Healthcare
Current phase
Phase 2

Tests whether it works, at what dose, in a few hundred people.

Mechanism
Undisclosed

The sponsor has not said how it is supposed to work.

Last public activity
August 2019
Copy last reviewed
September 2026
Record confidence
Low

A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.

Why it matters

Hair that does not come back after chemotherapy is a distinct problem from hair lost during it, and little is developed for it. CG428, a blend of citrus, cocoa, guarana and onion extracts, was tested both ways: Legacy's own Phase 2 in Switzerland, 40 women losing hair during chemotherapy, completed in 2019 without posting a result, and an academic pilot at Samsung Medical Center in 32 breast-cancer survivors with permanent loss found no significant difference from placebo in density or thickness, published in 2019. Nothing has been registered since. Legacy already appears in this register for Coacillium, a four-extract solution of similar composition; the two rows stay separate because the registrations do.

Development history

  1. Phase 2

    First Phase 2 trial on record: NCT02919735 — Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT02919735Phase 2Completed

    Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

    Legacy Healthcare SA · n=40 · October 2016

  • NCT02605629UnknownCompleted

    EValuation of the Impact of a TOpical Lotion on Permanent Chemotherapy Induced Hair Disorders in Cancer Survivors

    Samsung Medical Center · n=32 · July 2016

  • NCT02986412UnknownCompleted

    A 6-month Post-interventional Follow-up Extension of VOLUME Study (VOLUME-2)

    Samsung Medical Center · n=19 · January 2016

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources

Related programmes

Other programmes in the register with the same approach.

Home remedies that mention it

Cite this page

Hair Pipeline, "CG 428 — development record", hairpipeline.com/pipeline/cg-428